-The Times of India NEW DELHI: The government may negotiate prices of patented medicines with their manufacturers before allowing pharmaceutical companies to launch them in India. The move, a first of its kind, is also likely to be applied on patented drugs that are already being sold in the country, an official source said. An inter-ministerial committee, evaluating the mechanism to negotiate prices of patented medicines, has recently sought detailed information about...

-The Hindu In a significant development for the pharmaceutical industry, the Supreme Court has rejected multinational Bayer's appeal to block production and sales of the low cost version of its kidney cancer drug, sorafenib tosylate (branded as Nexavar), by Natco Pharmaceuticals. Hyderabad-based Natco was granted the first and to date only compulsory licence (CL) by the government in 2012 to make and sell a patented drug at a fraction of the...

-Down to Earth Government sidelines its committee of experts to set up new panel to review India's intellectual property rights policy The politics of protecting intellectual property rights (IPR) is becoming more curiouswith the commerce ministry setting up a think tank to draft a national IPR policy while sidelining a committee of experts it had set up earlier. Annoyed academics who were asked to help formulate the policy in July this year...

-The Indian Express It took the National Biodiversity Authority (NBA) six years, 18 drafts and a prod from the National Green Tribunal (NGT) to finalise the Guidelines for Access and Benefit Sharing (ABS) this August. Three months on, it is yet to notify the rules that would allow it to collect from domestic and foreign companies 0.1-1 per cent of their ex-factory gross sales of products using biological resources and traditional...

-The Business Standard A ray of hope for Indian generic drug makers Gilead Sciences, the California-headquartered biotechnology company, has authorised seven India-based drug makers - Cipla, Ranbaxy, Mylan, Strides Arcolab, Hetero, Cadila Healthcare and Sequent Scientific - to manufacture and sell the generic versions of its hepatitis C medicine, Sovaldi, in 91 developing countries. Earlier in the week, Lupin, the fourth largest Indian drug maker, announced that it will develop and supply...